S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)

Innate Pharma (IPHA) Short Interest Ratio & Short Volume

$2.50
+0.15 (+6.38%)
(As of 03:07 PM ET)

Innate Pharma Short Interest Data

Current Short Volume
76,900 shares
Previous Short Volume
89,100 shares
Change Vs. Previous Month
-13.69%
Dollar Volume Sold Short
$221,472.00
Short Interest Ratio / Days to Cover
7.7
Last Record Date
March 31, 2024
Outstanding Shares
80,860,000 shares
Percentage of Shares Shorted
0.10%
Today's Trading Volume
9,132 shares
Average Trading Volume
11,235 shares
Today's Volume Vs. Average
81%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Innate Pharma ?

Sign up to receive the latest short interest report for Innate Pharma and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

IPHA Short Interest Over Time

IPHA Days to Cover Over Time

IPHA Percentage of Float Shorted Over Time

Innate Pharma Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
3/31/202476,900 shares $221,472.00 -13.7%N/A7.7 $2.88
3/15/202489,100 shares $217,404.00 +13.7%N/A7.6 $2.44
2/29/202478,400 shares $205,408.00 -4.9%N/A4.1 $2.62
2/15/202482,400 shares $212,592.00 +8.4%N/A4.7 $2.58
1/31/202476,000 shares $203,680.00 -0.9%N/A4 $2.68
1/15/202476,700 shares $214,760.00 -8.9%N/A3.7 $2.80
12/31/202384,200 shares $235,760.00 +55.9%N/A3.9 $2.80
12/15/202354,000 shares $130,140.00 -5.9%N/A2.6 $2.41
11/30/202357,400 shares $137,760.00 -4.3%N/A4.3 $2.40
11/15/202360,000 shares $147,600.00 -6.0%N/A4.2 $2.46
10/31/202363,800 shares $151,844.00 +11.5%N/A4.4 $2.38
10/15/202357,200 shares $132,418.00 -8.5%N/A5 $2.32
9/30/202362,500 shares $158,125.00 -3.4%N/A6 $2.53
9/15/202364,700 shares $192,159.00 -1.5%N/A6.7 $2.97
8/31/202365,700 shares $191,324.97 -8.1%N/A5.2 $2.91
8/15/202371,500 shares $206,635.00 -3.8%N/A6.1 $2.89
7/31/202374,300 shares $218,442.00 -1.9%N/A6.8 $2.94
7/15/202375,700 shares $244,511.00 -3.8%N/A6.4 $3.23
6/30/202378,700 shares $242,002.50 +20.0%N/A6.1 $3.08
6/15/202365,600 shares $213,856.00 +9.7%N/A4 $3.26
5/31/202359,800 shares $175,812.00 -4.3%N/A3.8 $2.94
5/15/202362,500 shares $186,875.00 No ChangeN/A3.6 $2.99
10/31/2022147,600 shares $317,340.00 +12.8%N/A12.9 $2.15
10/15/2022130,900 shares $261,800.00 +15.5%N/A12.5 $2.00
9/30/2022113,300 shares $226,600.00 +1.3%N/A12.7 $2.00
9/15/2022111,900 shares $284,226.00 +2.3%N/A13.3 $2.54
8/31/2022109,400 shares $293,192.00 +0.2%N/A6.4 $2.68
8/15/2022109,200 shares $321,048.00 -10.1%N/A5.9 $2.94
7/31/2022121,500 shares $388,787.85 -3.6%N/A6.1 $3.20
7/15/2022126,000 shares $347,760.00 +0.3%N/A4.9 $2.76
6/30/2022125,600 shares $339,120.00 +3.9%N/A4.8 $2.70
6/15/2022120,900 shares $305,877.00 +1.9%N/A4.6 $2.53
5/31/2022118,700 shares $315,742.00 -13.6%N/A6.2 $2.66
5/15/2022137,300 shares $394,051.00 +8.0%N/A6.7 $2.87
4/30/2022127,100 shares $364,777.00 -9.3%N/A5.7 $2.87
4/15/2022140,100 shares $438,513.00 +4.0%N/A6 $3.13
3/31/2022134,700 shares $452,592.00 +105.0%N/A5.3 $3.36
3/15/202265,700 shares $207,612.00 +13.9%N/A1.6 $3.16
2/28/202257,700 shares $196,757.00 -2.5%N/A1 $3.41
2/15/202259,200 shares $219,632.00 -15.6%N/A0.9 $3.71
The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

IPHA Short Interest - Frequently Asked Questions

What is Innate Pharma's current short interest?

Short interest is the volume of Innate Pharma shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 76,900 shares of IPHA short. Learn More on Innate Pharma's current short interest.

What is a good short interest ratio for Innate Pharma?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IPHA shares currently have a short interest ratio of 8.0. Learn More on Innate Pharma's short interest ratio.

Is Innate Pharma's short interest increasing or decreasing?

Innate Pharma saw a drop in short interest in March. As of March 31st, there was short interest totaling 76,900 shares, a drop of 13.7% from the previous total of 89,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Innate Pharma's short interest compare to its competitors?

Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Innate Pharma: Acumen Pharmaceuticals, Inc. (2.88%), Opthea Limited (0.22%), Elevation Oncology, Inc. (12.58%), Cardiff Oncology, Inc. (7.63%), Kodiak Sciences Inc. (3.76%), Century Therapeutics, Inc. (7.62%), Compass Therapeutics, Inc. (1.97%), X4 Pharmaceuticals, Inc. (7.34%), Poseida Therapeutics, Inc. (6.70%), Graphite Bio, Inc. (2.56%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

What does it mean to sell short Innate Pharma stock?

Short selling IPHA is an investing strategy that aims to generate trading profit from Innate Pharma as its price is falling. IPHA shares are trading up $0.15 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Innate Pharma?

A short squeeze for Innate Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IPHA, which in turn drives the price of the stock up even further.

How often is Innate Pharma's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IPHA, twice per month. The most recent reporting period available is March, 31 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:IPHA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners